Affimed (AFMDQ) AI Stock Analysis

• Market Cap: $1.52K
• Dividend Yield: N/A
• Average Volume (3M): 57.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: -95.23%
• EPS Growth: 42.16%
• Country: US
• Employees: 76
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 15,227,463
• 10 Day Avg. Volume: 6,730
• 30 Day Avg. Volume: 57,126
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $0.25
• Price Target Upside: 1150.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: ―

Affimed's overall stock score reflects its financial struggles, with declining revenue and increasing losses being major concerns. The stock is technically weak, and the valuation is challenging due to negative earnings. Positive aspects from the earnings call, such as strategic progress in clinical trials and reduced losses, provide some optimism but are outweighed by financial and operational challenges.

Positive Factors

Potential Opportunities

Upcoming presentation at a major oncology meeting presents a potential opportunity to attract partners or funding.

Negative Factors

Financial Uncertainty

Management has not been able to raise additional funds to support its operations.

Insolvency Proceedings

Affimed announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.

Affimed Business Overview & Revenue Model

Company Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

How the Company Makes Money

Affimed primarily generates revenue through collaboration and license agreements with pharmaceutical companies, where they develop and commercialize their drug candidates. These agreements often include upfront payments, milestone payments based on the achievement of clinical, regulatory, and commercial milestones, and royalties on sales of commercialized products. Additionally, Affimed may receive funding from grants and research collaborations that support their development programs. Significant partnerships with larger pharmaceutical companies also contribute to their revenue by providing financial support and resources for advancing their therapeutic candidates through clinical trials.

Affimed Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Affimed Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AFMDQ, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.05, and below the 200-day MA of 1.17, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 31.31 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AFMDQ.

Affimed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BOLT	52 Neutral	$10.54M	―	-83.92%	―	-67.87%	0.40%
Sector *	51 Neutral	$7.43B	-0.36	-45.45%	2.27%	22.98%	-2.34%
SABS	51 Neutral	$22.49M	―	-127.48%	―	-95.87%	35.25%
EVAX	50 Neutral	$4.00M	―	-205.75%	―	2552.29%	60.70%
AFMDQ	42 Neutral	$1.52K	―		―	-95.23%	42.16%
ENTO	―	$3.10M	―	-33.24%	―	―	―
GRI	45 Neutral	$3.16M	―	-468.00%	―	―	98.17%